Insight Molecular Diagnostics Inc.
IMDX · XNASCIK 1642380fmd_1VZEPPC1HQZTPN4VS4TR5DX5NGManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2014 to Jun 30, 2026, 47 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 1 | 2 | 1 | 2 | 2 | 4 |
| Net interest income | (0) | (0) | (0) | 0 | (0) | (0) | (0) | (0) | (0) | (0) |
| Cost of revenue | – | – | – | – | 2 | 1 | 1 | 1 | 1 | 2 |
| Gross profit | – | – | – | – | (1) | 1 | (0) | 0 | 1 | 2 |
| Research and development | 6 | 7 | 7 | 7 | 10 | 5 | 7 | 9 | 10 | 16 |
| Selling, general and administrative | 5 | 12 | 9 | 15 | 23 | 23 | 23 | 14 | 14 | 17 |
| Total operating expenses | 11 | 19 | 15 | 22 | 29 | 55 | 18 | 26 | 62 | 53 |
| Operating income | (11) | (19) | (15) | (22) | (30) | (54) | (18) | (25) | (61) | (51) |
| Interest expense | 0 | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (0) | (1) | (1) | (0) | (1) | 1 | (1) | 0 | 0 | 1 |
| Income before taxes | – | – | – | (22) | (31) | (53) | (19) | (25) | (61) | – |
| Income tax expense | – | – | – | – | (1) | (9) | – | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | (30) | (44) | (19) | (25) | (61) | (50) |
| Net income | (11) | (19) | (16) | (22) | (30) | (64) | (73) | (28) | (61) | (50) |
| Net income to common shareholders | – | – | – | – | – | (64) | (73) | (29) | (61) | (50) |